Interferon in the treatment of cutaneous T-cell lymphoma.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Dermatologic Therapy

• Publication date

  1995-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0889-8588(18)30060-1PMID 14686974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T cell and cytokine patterns in leprosy skin lesions

  2004cited by this paper
• Interferon in the treatment of cutaneous T‐cell lymphoma

  2003cited by this paper
• Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

  2001cited by this paper
• Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.

  2001cited by this paper
• Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.

  2001cited by this paper
• Granulomatous slack skin: successful treatment withrecombinant interferon‐gamma

  2000cited by this paper
• Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin‐2 in a patient with the Sézary syndrome

  1999cited by this paper
• Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma.

  1999cited by this paper
• Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.

  1998cited by this paper
• The role of interferon in the therapy of malignant lymphoma.

  1996cited by this paper
• Interferons: Effectiveness, Toxicities, and Costs

  1996cited by this paper
• Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain).

  1996cited by this paper
• Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.

  1996cited by this paper
• Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.

  1996cited by this paper
• Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.

  1996cited by this paper
• The immunopathogenesis of cutaneous T-cell lymphoma.

  1995cited by this paper
• Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.

  1995cited by this paper
• Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.

  1995cited by this paper
• Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

  1995cited by this paper
• Treatment of neurotoxic side effects of interferon-alpha with naltrexone.

  1995cited by this paper
• Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome)

  1994cited by this paper
• The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C.

  1994cited by this paper
• Extracorporeal Photopheresis and Recombinant Interferon Alfa 2b in Sezary Syndrome: Use of Dual Marker Labeling to Monitor Therapeutic Response

  1994cited by this paper
• Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

  1993cited by this paper
• Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.

  1993cited by this paper
• Roferon-A in combination with Tigason in cutaneous T-cell lymphomas.

  1993cited by this paper
• Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.

  1993cited by this paper
• INTRAMUSCULAR LOW DOSE ALPHA‐2B INTERFERON AND ETRETINATE FOR TREATMENT OF MYCOSIS FUNGOIDES

  1993cited by this paper
• Interferon treatment of cutaneous T‐cell lymphoma

  1993cited by this paper
• Thyroid autoimmunity and hypothyroidism during long‐term treatment with recombinant interferon‐alpha

  1992cited by this paper
• Induction of myelo‐monocytic My7 antigen (CD13) expression by interferon‐α in basal cells of cutaneous T‐cell lymphomas

  1992cited by this paper
• Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.

  1992cited by this paper
• [Combination therapy with interferon alfa 2a and PUVA in cutaneous T-cell lymphoma].

  1992cited by this paper
• Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion.

  1992cited by this paper
• Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.

  1992cited by this paper
• Increase in 2′,5′‐oligoadenylate synthetase caused by deoxycoformycin in hairy cell leukaemia

  1992cited by this paper
• Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.

  1992cited by this paper
• Combination therapy with interferon alpha‐2b plus low‐dose interferon gamma in pretreated patients with Ph‐positive chronic myelogenous leukaemia

  1992cited by this paper
• Is interferon alpha in cutaneous T‐cell lymphoma a treatment of choice?

  1991cited by this paper
• Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids.

  1991cited by this paper
• A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies

  1991cited by this paper
• Role of interferon alfa-2b in the management of patients with advanced cutaneous T-cell lymphoma.

  1991cited by this paper
• Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.

  1991cited by this paper
• A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies.

  1991cited by this paper
• Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations.

  1991cited by this paper
• A phase II study alternating alpha‐2a‐interferon and gamma‐interferon therapy in patients with chronic myelogenous leukemia

  1991cited by this paper
• Actions of interferon alpha and interleukin- 1 beta on the glucose-responsive neurons in the ventromedial hypothalamus.

  1990cited by this paper
• Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.

  1990cited by this paper
• Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

  1990cited by this paper
• Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma.

  1990cited by this paper
• Interferon alpha‐2a in cutaneous T‐cell lymphoma

  1990cited by this paper
• Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

  1990cited by this paper
• Low-dose recombinant interferon-alpha in the treatment of cutaneous T-cell lymphomas.

  1989cited by this paper
• Regulation of immunoglobulin production in hyperimmunoglobulin E recurrent-infection syndrome by interferon gamma.

  1989cited by this paper
• Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.

  1989cited by this paper
• Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.

  1989cited by this paper
• Low‐dose recombinant interferon‐α in the treatment of cutaneous T‐cell lympbomas

  1989cited by this paper
• Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a.

  1989cited by this paper
• Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.

  1989cited by this paper
• Biologic response modifiers: the interferon alfa experience.

  1989cited by this paper
• [Gamma interferon therapy of cancer patients].

  1988cited by this paper
• The determination of an immunologically active dose of interferon-gamma in patients with melanoma.

  1988cited by this paper
• Low dosage alpha‐interferon treatment in patients with advanced cutaneous T‐cell lymphoma

  1988cited by this paper
• Anti-interferon antibodies: a perspective.

  1988cited by this paper
• Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate.

  1988cited by this paper
• Beta interferon in the treatment of mycosis fungoides.

  1988cited by this paper
• Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.

  1988cited by this paper
• Treatment of mycosis fungoides with recombinant interferon‐αza2 alone and in combination with etretinate

  1988cited by this paper
• Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.

  1987cited by this paper
• Recombinant interferon alfa‐2a, an active agent in advanced cutaneous t‐cell lymphomas

  1987cited by this paper
• Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle.

  1987cited by this paper
• Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy.

  1987cited by this paper
• [Evaluation of rIFN-gamma in the treatment of lymphoma and melanoma of the skin by systemic and intralesional administration].

  1987cited by this paper
• Alpha recombinant interferon in the treatment of mycosis fungoides (MF).

  1987cited by this paper
• Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).

  1987cited by this paper
• Lymphokines.

  1987cited by this paper
• Phase I/II Trial of Human Recombinant β-Interferon Serine in Patients with Renal Cell Carcinoma

  1986cited by this paper
• Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.

  1986cited by this paper
• Clinical toxicity of interferons in cancer patients: a review.

  1986cited by this paper
• Interferon treatment of human neoplasia.

  1986cited by this paper
• Synergistic Antiproliferative Effects of Human Recombinant α54- or βser-Interferon with γ-Interferon on Human Cell Lines of Various Histogenesis

  1986cited by this paper
• Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.

  1986cited by this paper
• Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy.

  1986cited by this paper
• The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas

  1986cited by this paper
• [Alpha interferon in the therapy of cutaneous T cell lymphomas].

  1986cited by this paper
• Alpha interferon in the treatment of hematologic malignancies.

  1986cited by this paper
• Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

  1986cited by this paper
• Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.

  1986cited by this paper
• Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.

  1985cited by this paper
• Intralesional interferon in the treatment of early mycosis fungoides.

  1985cited by this paper
• Interferons in the treatment of human cancer.

  1984cited by this paper
• Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons

  1984cited by this paper
• Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.

  1984cited by this paper
• Interferons with special emphasis on the immune system.

  1983cited by this paper
• A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.

  1982cited by this paper
• Indomethacin and aspirin do not inhibit the antiviral or anti-proliferative actions of interferon.

  1982cited by this paper
• THE TREATMENT OF MYCOSIS FUNGOIDES WITH PUVA *

  1980cited by this paper
• Establishment of the interferon-mediated antiviral state: role of fatty acid cyclooxygenase.

  1980cited by this paper
• Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon.

  1980cited by this paper
• Enhanced expression of HLA antigens and β2‐microglobulin on interferon‐treated human lymphoid cells

  1979cited by this paper

• Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025

  2025cites this paper
• Mycosis Fungoides, Sézary Syndrome, and Cutaneous B‐Cell Lymphomas: 2025 Update on Diagnosis, Risk‐Stratification, and Management

  2025cites this paper
• Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

  2025cites this paper
• Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome

  2025cites this paper
• Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies

  2024cites this paper
• Pegylated Interferon Combined With Low-Dose Total Skin Electron Beam Therapy for Advanced Stage Mycosis Fungoides: Two Case Reports and Literature Review

  2024cites this paper
• Pegylated interferon‐α2a in cutaneous T‐cell lymphoma – a multicenter retrospective data analysis with 70 patients

  2024cites this paper
• The efficacy of long‐term psoralen plus ultraviolet A and low‐dose interferon‐a combination therapy in mycosis fungoides: A literature review

  2024cites this paper
• Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/Sézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study.

  2024cites this paper
• Phototherapy restores deficient type I interferon production and enhances antitumor responses in mycosis fungoides.

  2023cites this paper
• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.

  2023cites this paper
• Real-World Clinical Characteristics, Management, and Outcomes of 44 Paediatric Patients with Hypopigmented Mycosis Fungoides

  2023cites this paper
• Transitioning to pegylated interferon for the treatment of cutaneous T-cell lymphoma: meeting the challenge of therapy discontinuation and a proposed algorithm

  2022cites this paper
• The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist’s Point of View

  2022cites this paper
• Phototherapy combined with systemic agents for mycosis fungoides

  2022cites this paper
• The use of interferon‐α2a as monotherapy in stage IB patients with mycosis fungoides: A retrospective chart review of patient outcomes

  2022cites this paper
• Mycosis fungoides und Sézary‐Syndrom

  2021cites this paper
• Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and Sezary syndrome. Prospective trial (NCT02323659)

  2021cites this paper
• Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy

  2021cites this paper
• Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

  2021cites this paper
• Mycosis fungoides and Sézary syndrome

  2021cites this paper
• How we treat mycosis fungoides and Sézary syndrome.

  2021cites this paper
• NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

  2020cites this paper
• The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

  2020cites this paper
• Management of primary cutaneous lymphomas during the COVID-19 pandemic

  2020cites this paper
• Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic.

  2020cites this paper
• The Immunopathogenesis and Immunotherapy of Cutaneous T Cell Lymphoma: Part II, Current and Future Approaches.

  2020cites this paper
• Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020

  2020cites this paper
• Cutaneous Lymphomas - Part I: Mycosis Fungoides, Sézary Syndrome, and CD30+ Cutaneous Lymphoproliferative Disorders.

  2020cites this paper
• How do we treat cutaneous T-cell lymphoma?

  2020cites this paper
• Cutaneous T Cell Lymphoma: A Difficult Diagnosis Demystified.

  2019cites this paper
• Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments

  2019cites this paper
• Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.

  2019cites this paper
• Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management

  2019cites this paper
• Special Considerations in the Treatment of Mycosis Fungoides

  2019cites this paper
• Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

  2019cites this paper
• Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T-cell lymphoma: results of a systematic review/meta-analysis.

  2019cites this paper
• STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia

  2018cites this paper
• Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.

  2018cites this paper
• The efficacy and safety of methotrexate versus interferon in cutaneous T-cell lymphomas

  2018cites this paper
• Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome

  2018cites this paper
• Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome

  2018cites this paper
• An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma

  2018cites this paper
• Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome

  2018cites this paper
• Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.

  2018cites this paper
• Novel Immunotherapies for T Cell Lymphoma and Leukemia

  2018cites this paper
• PUVA and interferon α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven‐year retrospective study in Russia

  2018cites this paper
• Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group

  2018cites this paper
• Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions

  2017cites this paper
• The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group.

  2017cites this paper
• Mycosis Fungoides and Sezary Syndrome.

  2017cites this paper
• European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

  2017cites this paper
• Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management

  2017cites this paper
• Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers

  2016cites this paper
• How I treat mycosis fungoides and Sézary syndrome.

  2016cites this paper
• Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents

  2016cites this paper
• A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

  2016cites this paper
• The Therapy of Cutaneous T Cell Lymphoma

  2016cites this paper
• T-cell lymphomas, a challenging disease: types, treatments, and future

  2016cites this paper
• Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.

  2016cites this paper
• Cutaneous T-Cell Lymphoma

  2016cites this paper
• Cutaneous T‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management

  2016cites this paper
• CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma.

  2015cites this paper
• Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.

  2015cites this paper
• Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod

  2015cites this paper
• Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.

  2015cites this paper
• The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.

  2015cites this paper
• Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.

  2015cites this paper
• Mycosis fungoides: therapeutic difficulties

  2015cites this paper
• Extracorporeal in the Treatment of Mycosis Fungoides and Sezary Syndrome

  2015cites this paper
• Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.

  2014cites this paper
• Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

  2014cites this paper
• New and established treatment options for mycosis fungoides and Sézary syndrome – an update

  2014cites this paper
• TG1042 (Adenovirus-interferon-γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial

  2014cites this paper
• Cutaneous T-cell lymphomas and their management strategies.

  2014cites this paper
• The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications.

  2014cites this paper
• Cutaneous T‐cell lymphoma: 2014 Update on diagnosis, risk‐stratification, and management

  2014cites this paper
• Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon‐induced apoptosis

  2013cites this paper
• Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

  2013cites this paper
• Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome

  2013cites this paper
• Immunotherapy for Cutaneous T-Cell Lymphoma

  2013cites this paper
• dendritic cell numbers and the production of cytokines populations: effects of CD40 ligand and treatment with GM-CSF on Sézary syndrome patients demonstrate a defect in dendritic cell

  2013cites this paper
• POUR LE DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma

  2012cites this paper
• Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

  2012cites this paper
• Treatment of cutaneous lymphomas: an update.

  2012cites this paper
• Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients.

  2012cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

  2011cites this paper
• Multicenter photopheresis intervention trial in early-stage mycosis fungoides.

  2011cites this paper
• Immune Response Modulators in the Treatment of Skin Cancer

  2011cites this paper
• Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

  2011cites this paper
• Cutaneous Diseases of the External Genitalia

  2011cites this paper
• Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

  2011cites this paper
• [Systemic treatment of cutaneous lymphomas].

  2011cites this paper
• Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

  2010cites this paper
• Lessons learned from the systematic evaluation of cutaneous T-cell lymphomas at the national cancer institute and the roadmap for future studies.

  2010cites this paper
• Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.

  2010cites this paper
• NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

  2010cites this paper